We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





AACC’s Disruptive Technology Award to Highlight Developers of AI and ML Technologies Advancing Medicine and Pathology

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Illustration
Illustration
Three finalists will compete live at the Disruptive Technology Award session at the 2021 American Association for Clinical Chemistry (AACC; Washington, DC, USA) Annual Scientific Meeting and a winner will be selected and announced at the conclusion of the session.

AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges. The 2021 Disruptive Technology Award finalists and their disruptive technologies include Day Zero Diagnostics, Inc. — DZD OneSeq Dx; Mammoth Biosciences — DETECTR; and MeMed — MeMed COVID-19 Severity.

The first finalist, Day Zero Diagnostics has developed a set of breakthrough capabilities that can provide a complete diagnosis of bloodstream infections and sepsis, including both the species ID and antibiotic susceptibility profile, in hours vs. days. Its technology enables the unprecedented recovery of pathogen whole genome sequences directly from clinical samples that may contain up to a billion times more human DNA. The company’s algorithms then interpret the genomic data to provide accurate, comprehensive organism ID and antibiotic susceptibility profiles. Day Zero Diagnostics enables a targeted treatment on day zero of hospital admission, resulting in better patient outcomes and cost savings.

The second finalist, Mammoth Biosciences has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

The third finalist, MeMed BV’s lead product accurately differentiates bacterial from viral (BV) infection, enabling improved patient management, including appropriate antibiotic use, in order to help address the global healthcare challenge of antimicrobial resistance. Based on computational integration of bacterial and viral-responsive immune proteins, Key delivers the BV result in 15 minutes from serum. This test was clinically validated on thousands of patients, is CE-marked and 510(k) pending.

The three finalists will present data on their technology in a special session during the Annual Scientific Meeting. During this session, a panel of expert judges will evaluate all presented testing solutions based on feasibility and performance. The audience will also vote for their favorite technology.

Related Links:
American Association for Clinical Chemistry

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
AACC

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.